NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), which took place on January 12 - 15, 2026 in Nassau, The Bahamas. The Company presented new clinical and preclinical data suppo ...

Core Argument - The mental health field should move beyond diagnosis and consider the individual's context, history, and societal influences [6][11][18] - Mental health diagnoses are valuable tools but should not overshadow the individual's unique experiences and the broader societal factors contributing to their distress [7][8] - Systemic oppression, societal expectations, and cultural realities significantly impact mental health, particularly for marginalized communities [5][12][13] Societal Impact on Mental Health - Societal structures and policies, such as discrimination and lack of inclusive education, contribute to mental health challenges [3][12][13] - The mental health field needs to understand the intersection of societal structures and individual experiences to provide effective treatment [14] - Stigma associated with mental health labels can perpetuate misunderstanding and reduce individuals to a set of symptoms [10] Holistic Approach to Mental Health - Mental health professionals, educators, families, and society should see the whole person, considering their context, culture, and history [11][18] - A compassionate and effective approach to mental health involves honoring the fullness of an individual's experience and recognizing their strengths [16][17] - Encourages a shift from asking "what is wrong with you" to "what happened to you" to understand the individual's pain and help them reclaim their strengths [19] Resilience and Empowerment - Despite challenges, individuals and communities demonstrate resilience in the face of adversity [14][15] - Empowering individuals by exploring their identity, community, and history can help them overcome mental health challenges [15][16] - Recognizing and honoring the strengths of individuals, such as creativity and meticulousness, can be an effective approach to mental health care [17]

Group 1 - Company atai Life Sciences is a clinical-stage biopharmaceutical firm focused on developing effective mental health treatments to improve patient outcomes [1][3] - The company has a pipeline of psychedelic-based therapies, including BPL-003 for treatment-resistant depression (TRD), VLS-01 for TRD, and EMP-01 for social anxiety disorder, all currently in Phase 2 clinical development [3] - atai is also working on a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD, aiming to provide scalable interventional psychiatry therapies [3] Group 2 - atai Life Sciences will participate in several investor conferences in September, including the Cantor Global Healthcare Conference on September 5, H.C. Wainwright Annual Global Investment Conference on September 8, and TD Cowen Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17 [1][2] - The format for these conferences will be fireside chats, and webcasts will be available on the company's website [2]

Core Insights - BrainsWay has made a strategic investment of $5 million in Neurolief, which is developing the Proliv™Rx device pending FDA approval for treating Major Depressive Disorder (MDD) outside of clinical settings [1][2][4] - Neurolief's technology aims to address the significant gap in accessible therapies for treatment-resistant MDD patients, who often face prolonged suffering and higher healthcare costs [3][4] - The partnership is expected to enhance both companies' market presence and expand access to innovative mental health treatments [2][4] Company Overview - BrainsWay is a leader in non-invasive neurostimulation treatments for mental health disorders, with its Deep TMS™ platform technology having three FDA-cleared indications [6][7] - Neurolief is a pioneering company focused on developing wearable, non-invasive neuromodulation systems for mental health and neurological disorders, with its Relivion®MG therapy already approved for migraine treatment [8] Financial Aspects - The investment agreement includes potential milestone-based funding, with a second tranche of up to $6 million contingent on FDA approval of Neurolief's Proliv™Rx system, and a third tranche of up to $5 million based on revenue milestones [4] - The strategic investment is seen as a validation of Neurolief's technology and vision, aiming to reshape the treatment landscape for depression [4]